Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial

• Published in: BMC neurology Vol. 21; no. 1; pp. 1 - 10
• Main Authors: Hutchison, R. Matthew, Evans, Karleyton C., Fox, Tara, Yang, Minhua, Barakos, Jerome, Bedell, Barry J., Cedarbaum, Jesse M., Brys, Miroslaw, Siderowf, Andrew, Lang, Anthony E.
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 23.11.2021; BioMed Central; BMC
• Subjects: Basal ganglia; Biological markers; Biomarker; Biomarkers; Brain diseases; Carrier proteins; Central nervous system diseases; Clinical medicine; Clinical trials; Computed tomography; CT imaging; Diagnosis; Diagnostic imaging; Dopamine; Dopamine receptors; Dopamine transporter; Drug dosages; Drug therapy; FDA approval; Health aspects; Methods; Monoclonal antibodies; Movement disorders; Nerve endings; Neurodegenerative diseases; Parkinson's disease; Regulatory approval; Single photon emission computed tomography; SPECT; SWEDD; Synuclein; Testing; Thyroid gland; Tomography; Tremor (Muscular contraction); Work stations; United States; United States > US

Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of...